Internal Reference Number: FOI_7182
Date Request Received: 16/05/2023 00:00:00
Date Request Replied To: 19/06/2023 00:00:00
This response was sent via: By Email
Request Summary: Treatment of Ovarian cancer
Request Category: Companies
| Question Number 1: How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one? | |
| Answer To Question 1: 8 | |
| Question Number 2: How many ovarian cancer patients (any stage) have been treated in the last 3 months with: 鈥� Paclitaxel in combination with a platinum-based compound 鈥� Platinum-based therapy alone (cisplatin or carboplatin) 鈥� Bevacizumab in combination with paclitaxel and carboplatin 鈥� Olaparib 鈥� Olaparib + Bevacizumab 鈥� Niraparib 鈥� Rucaparib | |
| Answer To Question 2: 鈥� Paclitaxel in combination with a platinum-based compound 10 鈥� Platinum-based therapy alone (cisplatin or carboplatin) <5 鈥� Bevacizumab in combination with paclitaxel and carboplatin <5 鈥� Olaparib <5 (patients on monotherapy during the 3 month period but previously on Olaparib and bevacizumab) 鈥� Olaparib + Bevacizumab <5 鈥� Niraparib <5 鈥� Rucaparib 5 | |
| Question Number 3: Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part. | |
| Answer To Question 3: No | |
| Question Number 4: If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with: 鈥� Olaparib 鈥� Olaparib + Bevacizumab 鈥� Niraparib 鈥� Other treatments | |
| Answer To Question 4: 鈥� Olaparib <5 鈥� Olaparib + Bevacizumab <5 鈥� Niraparib 0 鈥� Other treatments - 鈥淭he Trust does not hold this information鈥�. | |
| Question Number 5: If data for HRD (homologous recombination deficiency) and BRCA testing is available, please provide how many HRD positive BRCA mutated patients were treated in the last 3 months with: 鈥� Olaparib 鈥� Olaparib + Bevacizumab 鈥� Niraparib 鈥� Other treatments | |
| Answer To Question 5: 鈥� Olaparib <5 鈥� Olaparib + Bevacizumab <5 鈥� Niraparib 0 鈥� Other treatments - 鈥淭he Trust does not hold this information鈥�. | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of 看片软件 Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
